TrialPloS one2015

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.

Janaki Amin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.